{"id":"ndl-pdt","safety":{"commonSideEffects":[{"rate":null,"effect":"Phototoxicity/photosensitivity"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Burning/pain at treatment site"},{"rate":null,"effect":"Crusting/scaling"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NDL-PDT (Galderma's proprietary photodynamic therapy formulation) works by combining a photosensitizing agent with light activation to produce cytotoxic reactive oxygen species that damage and destroy diseased cells. This mechanism is particularly suited for dermatological applications where localized light delivery can be precisely controlled. The drug is designed to selectively target and ablate pathological tissue while minimizing damage to surrounding healthy skin.","oneSentence":"NDL-PDT is a photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy targeted tissue.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:50:28.166Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis"},{"name":"Non-melanoma skin cancer"}]},"trialDetails":[{"nctId":"NCT01821391","phase":"PHASE3","title":"Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2013-07","conditions":"Actinic Keratoses","enrollment":131}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Metvix NDL-PDT"],"phase":"phase_3","status":"active","brandName":"NDL-PDT","genericName":"NDL-PDT","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NDL-PDT is a photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy targeted tissue. Used for Actinic keratosis, Non-melanoma skin cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}